Drug Discovery Core, University/BHF Centre for Cardiovascular Science, Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom.
Methods Appl Fluoresc. 2017 Dec 15;6(1):015002. doi: 10.1088/2050-6120/aa8c60.
The assessment of drug-target engagement for determining the efficacy of a compound inside cells remains challenging, particularly for difficult target proteins. Existing techniques are more suited to soluble protein targets. Difficult target proteins include those with challenging in vitro solubility, stability or purification properties that preclude target isolation. Here, we report a novel technique that measures intracellular compound-target complex formation, as well as cellular permeability, specificity and cytotoxicity-the toxicity-affinity-permeability-selectivity (TAPS) technique. The TAPS assay is exemplified here using human kynurenine 3-monooxygenase (KMO), a challenging intracellular membrane protein target of significant current interest. TAPS confirmed target binding of known KMO inhibitors inside cells. We conclude that the TAPS assay can be used to facilitate intracellular hit validation on most, if not all intracellular drug targets.
评估化合物在细胞内的药物靶标结合情况以确定其疗效仍然具有挑战性,特别是对于难靶标蛋白而言。现有的技术更适用于可溶性蛋白靶标。难靶标蛋白包括那些具有挑战性的体外可溶性、稳定性或纯化特性的靶标,这些特性会妨碍靶标分离。在这里,我们报告了一种新的技术,用于测量细胞内化合物-靶标复合物的形成,以及细胞通透性、特异性和细胞毒性——毒性-亲和力-通透性-选择性(TAPS)技术。本文以人犬尿氨酸 3-单加氧酶(KMO)为例,说明了 TAPS 检测方法,KMO 是目前具有重要研究意义的具有挑战性的细胞内膜蛋白靶标。TAPS 证实了已知 KMO 抑制剂在细胞内的靶标结合。我们得出结论,TAPS 检测方法可用于促进大多数(如果不是全部)细胞内药物靶标的细胞内命中验证。